ada standards of care 2025 glp-1 receptor agonists recommendations Nutritional priorities to support therapy for obesity: a joint Advisory from the American College Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society - The American Diabetes Association Releases

Discover how once-monthly maridebart cafraglutide for the treatment of obesity works, its clinical trial evidence, potential eligibility criteria, side effects, and the pathway to NHS access if approved by UK regulators.

This bundle features our High-Potency Multi, formulated to address common nutrient deficiencies, and our Dual-Action Probiotic, which combines a clinically-studied probiotic strain, prebiotic fibre, and ginger to promote digestive comfort

Partly through these actions, GLP-1 receptor agonism was shown to reduce cardiovascular disease (CVD) in people with T2D with previous CVD or at high-risk thereof

However, there was no significant difference in adverse CVEs or all-cause mortality when compared with those taking SGLT2 inhibitors

Prebiotic Chicory Inulin- Digestive & Immune Health*

A newly published clinical investigation in the British Journal of Anaesthesia (May 2025 issue) reveals compelling evidence linking glucagon-like peptide-1 receptor agonists (GLP-1RAs) to impaired gastric emptying (IGE)